Does the media favor ACAD or MNKD?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than MannKind. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 2 mentions for MannKind. ACADIA Pharmaceuticals' average media sentiment score of 1.39 beat MannKind's score of -0.69 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media refer more to MNKD or DYN?

In the previous week, Dyne Therapeutics had 20 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Dyne Therapeutics and 2 mentions for MannKind. Dyne Therapeutics' average media sentiment score of 0.23 beat MannKind's score of -0.69 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Dyne Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MNKD or EWTX?

In the previous week, Edgewise Therapeutics had 5 more articles in the media than MannKind. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 2 mentions for MannKind. Edgewise Therapeutics' average media sentiment score of 0.62 beat MannKind's score of -0.69 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MNKD or CELC?

MannKind has higher revenue and earnings than Celcuity. MannKind is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.82 $5.86M -$0.13 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is MNKD or CELC more profitable?

Celcuity has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -11.08% -11.21% -6.31% Celcuity N/A -350.78% -41.54%

Does the media prefer MNKD or CELC?

In the previous week, Celcuity had 9 more articles in the media than MannKind. MarketBeat recorded 11 mentions for Celcuity and 2 mentions for MannKind. Celcuity's average media sentiment score of 0.23 beat MannKind's score of -0.69 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, MNKD or PBLS?

MannKind has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.82 $5.86M -$0.13 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media favor MNKD or PBLS?

In the previous week, Parabilis Medicines had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Parabilis Medicines and 2 mentions for MannKind. Parabilis Medicines' average media sentiment score of 0.78 beat MannKind's score of -0.69 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MannKind (MNKD) Competitors

$4.15 -0.11 (-2.58%)

As of 08/21/2026 04:00 PM Eastern

Compare

MNKD vs. ACAD, DYN, EWTX, CELC, and PBLS

Should you buy MannKind stock or one of its competitors? MannKind's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Edgewise Therapeutics (EWTX), Celcuity (CELC), and Parabilis Medicines (PBLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MannKind compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than MannKind. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 2 mentions for MannKind. ACADIA Pharmaceuticals' average media sentiment score of 1.39 beat MannKind's score of -0.69 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

ACADIA Pharmaceuticals presently has a consensus price target of $34.19, indicating a potential upside of 15.91%. MannKind has a consensus price target of $9.22, indicating a potential upside of 122.14%. Given MannKind's higher possible upside, analysts clearly believe MannKind is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, MannKind has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to MannKind's net margin of -11.08%. ACADIA Pharmaceuticals' return on equity of 9.03% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
MannKind	-11.08%	-11.21%	-6.31%

ACADIA Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.74	$391M	$2.22	13.29
MannKind	$348.97M	3.82	$5.86M	-$0.13	N/A

Summary

ACADIA Pharmaceuticals beats MannKind on 14 of the 16 factors compared between the two stocks.

How does MannKind compare to Dyne Therapeutics?

MannKind (NASDAQ:MNKD) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Dyne Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Dyne Therapeutics	N/A	-64.30%	-50.33%

MannKind presently has a consensus price target of $9.22, suggesting a potential upside of 122.14%. Dyne Therapeutics has a consensus price target of $34.42, suggesting a potential upside of 31.86%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

MannKind has higher revenue and earnings than Dyne Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.82	$5.86M	-$0.13	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

In the previous week, Dyne Therapeutics had 20 more articles in the media than MannKind. MarketBeat recorded 22 mentions for Dyne Therapeutics and 2 mentions for MannKind. Dyne Therapeutics' average media sentiment score of 0.23 beat MannKind's score of -0.69 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Dyne Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

49.6% of MannKind shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MannKind has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Summary

Dyne Therapeutics beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Edgewise Therapeutics?

MannKind (NASDAQ:MNKD) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

MannKind has higher revenue and earnings than Edgewise Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.82	$5.86M	-$0.13	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Edgewise Therapeutics had 5 more articles in the media than MannKind. MarketBeat recorded 7 mentions for Edgewise Therapeutics and 2 mentions for MannKind. Edgewise Therapeutics' average media sentiment score of 0.62 beat MannKind's score of -0.69 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Edgewise Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

MannKind currently has a consensus target price of $9.22, suggesting a potential upside of 122.14%. Edgewise Therapeutics has a consensus target price of $50.33, suggesting a potential upside of 13.93%. Given MannKind's higher probable upside, equities analysts clearly believe MannKind is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

MannKind and Edgewise Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does MannKind compare to Celcuity?

MannKind (NASDAQ:MNKD) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Celcuity had 9 more articles in the media than MannKind. MarketBeat recorded 11 mentions for Celcuity and 2 mentions for MannKind. Celcuity's average media sentiment score of 0.23 beat MannKind's score of -0.69 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind currently has a consensus target price of $9.22, indicating a potential upside of 122.14%. Celcuity has a consensus target price of $154.55, indicating a potential upside of 65.24%. Given MannKind's higher probable upside, equities research analysts clearly believe MannKind is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

MannKind has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

MannKind has higher revenue and earnings than Celcuity. MannKind is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.82	$5.86M	-$0.13	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Celcuity has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Celcuity	N/A	-350.78%	-41.54%

Summary

Celcuity beats MannKind on 8 of the 15 factors compared between the two stocks.

How does MannKind compare to Parabilis Medicines?

MannKind (NASDAQ:MNKD) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Parabilis Medicines had 1 more articles in the media than MannKind. MarketBeat recorded 3 mentions for Parabilis Medicines and 2 mentions for MannKind. Parabilis Medicines' average media sentiment score of 0.78 beat MannKind's score of -0.69 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.82	$5.86M	-$0.13	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Parabilis Medicines has a net margin of 0.00% compared to MannKind's net margin of -11.08%. Parabilis Medicines' return on equity of 0.00% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Parabilis Medicines	N/A	N/A	N/A

MannKind presently has a consensus price target of $9.22, indicating a potential upside of 122.14%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 5.86%. Given MannKind's higher possible upside, research analysts plainly believe MannKind is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Parabilis Medicines beats MannKind on 7 of the 12 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.37B	$3.96B	$7.27B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	11.09%
P/E Ratio	-31.92	11.52	270.68	24.19
Price / Sales	3.82	1,405.76	639.40	109.85
Price / Cash	68.85	103.29	76.89	53.23
Price / Book	-19.76	17.90	13.43	6.37
Net Income	$5.86M	-$12.50M	$3.46B	$347.74M
7 Day Performance	7.79%	3.23%	2.15%	0.06%
1 Month Performance	8.07%	7.72%	6.18%	2.86%
1 Year Performance	0.97%	55.10%	24.96%	17.13%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	2.5024 of 5 stars	$4.15 -2.6%	$9.22 +122.1%	+5.3%	$1.37B	$348.97M	N/A	400
ACAD ACADIA Pharmaceuticals	4.5241 of 5 stars	$29.01 +2.7%	$34.19 +17.9%	+19.0%	$4.87B	$1.07B	13.07	510
DYN Dyne Therapeutics	3.5433 of 5 stars	$26.15 +1.8%	$34.42 +31.6%	+113.6%	$4.80B	N/A	N/A	100	Analyst Revision
EWTX Edgewise Therapeutics	2.3057 of 5 stars	$44.04 -0.3%	$49.08 +11.5%	+202.2%	$4.80B	N/A	N/A	60	Analyst Forecast
CELC Celcuity	3.3616 of 5 stars	$92.44 +0.5%	$154.55 +67.2%	+85.6%	$4.49B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. ACAD, DYN, EWTX, CELC, and PBLS

How does MannKind compare to ACADIA Pharmaceuticals?

Summary

How does MannKind compare to Dyne Therapeutics?

Summary

How does MannKind compare to Edgewise Therapeutics?

Summary

How does MannKind compare to Celcuity?

Summary

How does MannKind compare to Parabilis Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. ACAD, DYN, EWTX, CELC, and PBLS

How does MannKind compare to ACADIA Pharmaceuticals?

Does the media favor ACAD or MNKD?

Do analysts recommend ACAD or MNKD?

Do insiders & institutionals hold more shares of ACAD or MNKD?

Which has more risk & volatility, ACAD or MNKD?

Is ACAD or MNKD more profitable?

Which has better valuation and earnings, ACAD or MNKD?

Summary

How does MannKind compare to Dyne Therapeutics?

Is MNKD or DYN more profitable?

Do analysts recommend MNKD or DYN?

Which has preferable earnings & valuation, MNKD or DYN?

Does the media refer more to MNKD or DYN?

Do insiders & institutionals have more ownership in MNKD or DYN?

Which has more volatility and risk, MNKD or DYN?

Summary

How does MannKind compare to Edgewise Therapeutics?

Which has stronger valuation & earnings, MNKD or EWTX?

Does the media refer more to MNKD or EWTX?

Which has more volatility & risk, MNKD or EWTX?

Do insiders and institutionals have more ownership in MNKD or EWTX?

Is MNKD or EWTX more profitable?

Do analysts recommend MNKD or EWTX?

Summary

How does MannKind compare to Celcuity?

Do insiders & institutionals believe in MNKD or CELC?

Does the media prefer MNKD or CELC?

Do analysts recommend MNKD or CELC?

Which has more volatility and risk, MNKD or CELC?

Which has higher valuation & earnings, MNKD or CELC?

Is MNKD or CELC more profitable?

Summary

How does MannKind compare to Parabilis Medicines?

Does the media favor MNKD or PBLS?

Which has preferable earnings and valuation, MNKD or PBLS?

Is MNKD or PBLS more profitable?

Do analysts prefer MNKD or PBLS?

Do institutionals and insiders believe in MNKD or PBLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools